GlassScriptPhysician profile
Anthony S Shen
NPI 1831160761
$12,846.26
in general payments reported to CMS, 2019-2025
36 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,106 · 2020: $2,518 · 2021: $2,958 · 2022: $2,829 · 2023: $1,408 · 2024: $27.68.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,436.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,435.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $2,252.78 | 2019-2023 | Trelegy Ellipta, Nucala, Arexvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $2,168.23 | 2019-2023 | Ofev, Spiriva Respimat, Stiolto Respimat |
| Astrazeneca Pharmaceuticals LP | $1,667.42 | 2019-2023 | Breztri, Fasenra, Tezspire |
| Actelion Pharmaceuticals US, INC. | $1,392.15 | 2019-2023 | Opsumit |
| Insmed, INC. | $694.91 | 2019-2023 | Arikayce |
| Grifols USA, LLC | $582.73 | 2019-2023 | Prolastin-C Liquid |
| Regeneron Healthcare Solutions, INC. | $407.34 | 2019-2023 | Dupixent |
| Electromed, INC. | $391.06 | 2019-2024 | Smartvest |
| Genzyme Corporation | $354.93 | 2019-2023 | |
| United Therapeutics Corporation | $337.82 | 2019-2023 | Tyvaso |
| Bayer Healthcare Pharmaceuticals INC. | $326.62 | 2019-2023 | |
| Jazz Pharmaceuticals INC. | $302.63 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $261.95 | 2019-2022 | |
| Mylan Specialty L.P. | $246.86 | 2019-2023 | Yupelri |
| Philips North America LLC | $183.63 | 2022-2023 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Advanced Respiratory, INC | $168.27 | 2019-2021 | |
| Sunovion Pharmaceuticals INC. | $156.56 | 2019 | |
| Pfizer INC. | $133.79 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $116.58 | 2019-2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $81.13 | 2020-2021 | |
| Janssen Pharmaceuticals, INC | $71.36 | 2019-2021 | |
| Amgen INC. | $63.61 | 2022-2023 | Tezspire |
| Gilead Sciences, INC. | $58.13 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $51.88 | 2019-2021 | |
| Genentech USA, INC. | $50.94 | 2019-2021 | |
| Circassia INC. | $46.35 | 2019 | |
| Shire North American Group INC | $45.75 | 2019 | |
| Fisher & Paykel Healthcare INC | $43.91 | 2020-2021 | |
| Inogen, INC. | $41.43 | 2021 | |
| Harmony Biosciences LLC | $33.11 | 2021 | |
| Cumberland Pharmaceuticals, INC. | $24.78 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $23.78 | 2021 | |
| Axsome Therapeutics, INC. | $20.42 | 2023 | Sunosi |
| Pulmonx Corporation | $14.62 | 2023 | Zephyr Endobronchial Valve, Zephyr Delivery Catheter, Chartis Catheter |
| Apria Healthcare LLC | $14.46 | 2021 | |
| Resmed Corp | $14.34 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anthony Shen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.